CD274 and non-small cell lung carcinoma: The KEYNOTE‐042 study indicated that in NSCLC patients whose PD-L1 tumor proportion score was ≥1%, pembrolizumab monotherapy prolonged their survival for longer than with traditional chemotherapy (8).